Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

EAB Group Plc’ financial statements bulletin 2019 – The Group’s IFRS turnover and comparable net turnover decreased by 7%, and its loss for the period was EUR 1.5 million

EAB Group Plc, Stock Exchange Release, 14 February 2020 at 9.00 a.m. (EET) EAB Group Plc’ financial statements bulletin 2019 – The Group’s IFRS turnover and comparable net turnover decreased by 7%, and its loss for the period was EUR 1.5 million EAB Group’s (hereinafter “EAB” or “the Group”) IFRS turnover for the period 1 January–31 December 2019 was EUR 18.4 million (EUR 19.6 million in 2018), and its loss for the period was EUR 1.5 million (profit of EUR 1.4 million in 2018). The Group’s operating result was EUR -1.3 million (EUR 1.8 million in 2018). The turnover included EUR 10.6

The Board of Directors of Alma Media Corporation decided on new plan periods within the share-based long-term incentive schemes for key employees

Alma Media Corporation           Stock Exchange Release    14 February 2020 at 9.00 a.m. THE BOARD OF DIRECTORS OF Alma Media Corporation DECIDED ON NEW PLAN PERIODS WITHIN THE SHARE-BASED LONG-TERM INCENTIVE SCHEMES FOR KEY EMPLOYEES The Board of Directors of Alma Media Corporation has decided on a new plan period in the share-based long-term incentive scheme of the Company’s top management. The Board of Directors, at the same time, decided on a new plan period in the share-based long-term incentive scheme for the other key personnel of Alma Media Corporation. The new plan structures

AZN: Full-year and Q4 2019 results

AstraZeneca PLC 14 February 2020 7:00 GMT Full-year and Q4 2019 results A year of significant innovation for patients; accelerating the strategic transition AstraZeneca delivered a year of strong revenue growth, supported by the launch of new medicines[1] and further good progress on its pipeline, with several approvals and data readouts. These trends are set to continue in 2020, accompanied by growth in earnings and cash. In maintaining its focus on patients and science, the Company remains on track to deliver its strategic ambitions. Full-year Product Sales growth of 12% (

2019 Year-End Report and Interim Report October – December 2019

The complete report is available on the Company’s website info.bimobject.com.  Fourth quarter 2019 · Invoiced sales amounted to SEK 60 (59) million. Web Services (ARR) saw healthy growth of 31% in the quarter. · The distribution between projects and web services (subscriptions) was 29/71 (42/58) percent. · High proportion of sales were invoiced late in the quarter which impacted net sales negatively as revenue recognition will occur in 2020. The Group’s net sales decreased by 20 percent to SEK 31 (39) million. · The Group’s operating loss amounted to SEK -43 (-34) million

YEAR-END REPORT   January - December 2019

THE HIGHEST LEVEL OF CUSTOMER ACTIVITIES TO DATE AND FOCUS ON COMMERCIALISATIONFinancial summary: The fourth quarter 2019 · Net sales amounted to 882 tsek (502 tsek for the corresponding quarter in 2018) · Other revenues (excl. activated development costs) were 83 tsek (0) · Earnings before interest and tax became -7 216 tsek (-6 933) · Net earnings per share amounted to -0,27 sek (-0,27) The full year 2019 · Net sales amounted to 2 143 tsek (1 451 in 2018) · Other revenues (excl. activated development costs) were 193 tsek (105) · Earnings before interest and

IMPACT COATINGS AB (PUBL), YEAR-END REPORT 2019

FINANCIAL RESULTS FULL YEAR 2019 · Net revenue amounted to SEK 49 084 thousand (20 194) · Total income amounted to SEK 39 366 thousand (30 609) · Operating profit amounted to SEK -26 368 thousand (-37 568) · Operating profit after financial items amounted to SEK -26 387 thousand (-37 593) · Cash flow amounted to SEK 32 116 thousand (-18 717) · Equity-to-assets ratio amounted to 666% (159) · Order backlog at period end amounted to EUR 289 thousand · No dividend is proposed FINANCIAL RESULTS FOURTH QUARTER 2019 · Net revenue amounted to SEK 20 574 thousand (7

GCA expands its sector and geographic footprint via acquisition of Stella EOC

Combination expands GCA’s coverage across key M&A markets in Europe and further strengthens its leading global Technology and Media practice· GCA Corporation is a leading global investment bank focused on growth companies · Stella EOC is an established M&A boutique having completed over 230 transactions since formation · Stella EOC will be fully integrated into GCA’s business with immediate effect · Transaction adds key markets in the Nordics and Benelux to GCA’s coverage across Europe, the US and Asia · Stella EOC’s leading position in several technology verticals and in the

Clas Ohlson to invest 27 MSEK in MatHem

The collaboration with MatHem in Sweden is an important part of Clas Ohlson's strategy to establish a unique position in terms of availability and convenience for our customers. Clas Ohlson currently owns 8.1% of the MatHem company, that today announced a funding round in which Clas Ohlson commits to invest 27 MSEK.Clas Ohlson's investment in MatHem in December 2017 was the launchpad for an important and successful strategic collaboration. Today, MatHem is the leading independent pure-play online grocery retailer in Sweden and offers a broad range of grocery products and related domestic

Hufvudstaden launches Cecil – a new concept in coworking

Hufvudstaden will open Cecil Coworking in Bibliotekstan, Stockholm in early 2021. It will be the real estate company’s first co-working facility under its own management. Cecil Coworking is a concept that offers workspaces in an attractive location, first-class service and a professional network. It will be a premium space of approximately 3,000 square metres with about 300 office spaces.There has been strong growth in the market for flexible, shared offices in recent years. Many companies are saying they would rather buy a service package than office space and would prefer to be part of a

Year-end report 1 January – 31 December 2019

Fourth quarter (1 October – 31 December 2019) · Net sales for the quarter amounted to MSEK 247 (90). · Operating profit/loss before depreciation and amortisation (EBITDA) amounted to MSEK 147 (46). · Operating profit/loss (EBIT) totalled MSEK 128 (28). · Profit/loss before tax (EBT) amounted to MSEK 108 (5). · Profit after tax totalled MSEK 98 (2), corresponding to SEK 2.93 (0.07) per share before dilution and 2.29 (0.07) after dilution. · Operating cash flow was MSEK 196 (30). · Production from Own wind power operations was 89 GWh (85). · Average income from Own

Year-End Report Jetpak Top Holding AB (publ) 1 January – 31 December 2019

Quarter 4: 1 October - 31 December 2019 · Total revenue increased by 0.7% to TSEK 218,113 (216,643), of which underlying organic growth amounts to 1.9% · Net sales decreased by 0.9% to TSEK 209,565 (211,480) · Operating profit amounts to TSEK 22,360 (13,694), of which non-recurring costs charged in the amount of TSEK 593 (6,298) · Profit/loss for the period amounts to TSEK 18,635 (-10,293) · Earnings per share is SEK 1.55 (-2.56) · Cash flow from current operations amounts to TSEK 43,793 (23,491). Period: 1 January - 31 December 2019  · Total revenue increased by 4.

IRRAS AB publishes Interim Report for the period January to December 2019

A Year of Accomplishments Laying the Foundation for Future Growth ” The fourth quarter of 2019 was an important period of progress for IRRAS. We accomplished the remaining corporate milestones for the year, highlighted by the renewed CE Mark for the IRRAflow® catheter in the European Union (EU) and the launch of our Hummingbird ICP Monitoring product line in the United States (US). Importantly, our impact to patients continues to broaden and deepen. Since the launch of IRRAflow, we have completed successful patient treatments in seven major markets, including the US, Germany, Finland,

Eltel Group: Full-year report January–December 2019

October–December 2019 · Net sales EUR 278.9 million (330.9). Total growth -15.7% and organic growth[1] in Power and Communication -10.9% · Operative EBITA[2] EUR -14.9 million (2.9) and operative EBITA margin -5.3% (0.9) · Operating result (EBIT) EUR -13.7 million (-0.2) and EBIT margin -4.9% (-0.1) · Net result EUR -11.8 million (-3.3) · Earnings per share EUR -0.08 (-0.02), basic and diluted · Cash flow from operating activities EUR 65.0 million. The comparable cash flow from operating activities before IFRS 16 impact[3] was EUR 59.5 million (70.0). January–December

TietoEVRY starts repurchasing own shares

TietoEVRY Corporation        STOCK EXCHANGE RELEASE        14 February 2020 9.00 EET The Board of Directors of TietoEVRY Corporation has decided to start a repurchasing programme of the company's own shares based on the authorization given by the Annual General Meeting on 21 March 2019. The company has a weighty financial reason for the directed acquisition of its shares, since the shares are acquired for purposes of share-based incentive programmes for key personnel. The purchases of the shares will start on 17 February 2020 at the earliest and end on 9 March 2020 at the latest.

Immunovia Full Year report 2019

“I am incredibly proud of the progress we made during 2019, especially in reaching the important milestone in December 2019 where we showed 95% accuracy for the upcoming commercialization of IMMray™ PanCan-d in diagnosing pancreatic cancer at a stage where it can still be operated on. This result opens the way for a significant improvement in care and an improved survival rate for patients suffering from this deadly disease. At Immunovia, we remain focused on introducing our blood-based test to the market in Q3 2020.With two milestones remaining – a verification study and a final validation

Year-end Report January–December 2019

Fourth quarter 2019 · Revenues amounted to SEK 25 362 thousand (20 425), an increase of 24 percent · Profit before depreciations and amortizations (EBITDA) amounted to SEK -19 877 thousand (-16 050) · Result amounted to SEK -22 784 thousand (-16 904) · Earnings per share amounted to SEK -0,17 (-0,14) · Equity per share amounted to SEK 2,19 (2,30) January–December 2019 · Revenues amounted to SEK 96 355 (71 485) thousand, an increase of 35 percent · Result before depreciations and amortizations (EBITDA) amounted to SEK -48 322 thousand (-52 589) · Result amounted

Westmark Manor to be Released Summer 2020

Today EG7 announces that the title Westmark Manor will be launched in early summer 2020. Westmark Manor is a story-driven survival game with elements of horror, mystery and the occult. The title is developed by Nodbrim Interactive and is published by Toadman Studios, that is entitled to a share of the revenue generated by the game. The title will initially be digitally distributed through Steam. Nodbrim Interactive is run by Toadman Studios’ own developers and Westmark Manor is the first step in EG7's initiative to support its developers' personal projects. Comment by Robin Flodin,

LeoVegas AB Q4: Quarterly report 1 October– 31 December 2019. LeoVegas reiterates its long-term financial targets, remove short term financial targets and raises the dividend

“We have entered 2020 with good underlying growth and profitability, and an ever-stronger balance sheet”– Gustaf Hagman, Group CEO FOURTH QUARTER 2019: 1 october–31 december 2019[1] · Revenue increased by 3% to EUR 87.1 m (84.5). · EBITDA was EUR 14.5 m (8.1), corresponding to an EBITDA margin of 16.7% (9.6%) · Adjusted EBITDA was EUR 9.2 m (8.1), corresponding to a margin of 10.6% (9.6%). · The number of depositing customers was 351,613 (327,156), an increase of 7%.   · The number of returning depositing customers was record-high 207,982 (181,747), an increase of 14%.

Nexam Chemical Holding AB (publ) Year-End Report 1 January – 31 December 2019

106 percent sales growth for NEXAMITE® and NEXIMID® during the yearSignificant events: · Sales growth continues, +8% compared to the corresponding quarter in 2018. · The NEXAMITE® and NEXIMID®-based range, Performance Chemicals, in strong growth. + 36% compared to the corresponding quarter of 2018, the growth mainly attributable to products intended for PET foam manufacturing. The growth for Performance Chemicals for the full year 2019 was + 106%. · Sales in the color and additive masterbatch, Performance Masterbatch, were -7% compared to the corresponding quarter of 2018. For

2019 year-end financial report: Sites opened for recruitment to the pivotal Phase III study SPARKLE

Ascelia Pharma AB (publ) (ticker: ACE) today published its year-end report for the period July 2019 – December 2019, which is now available on the company’s website (the financial year will going forward follow the calendar year): https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN THE PERIOD · Julie Waras Brogren appointed as Chief Commercial Officer · Detailed preparations ahead of the start of the Phase III study SPARKLE with Mangoral · Four sites opened for patient enrollment in December and one additional site opened in January 2020 for the SPARKLE study

Notice of Kesko’s Annual General Meeting

Shareholders of Kesko Corporation are invited to the Annual General Meeting to be held at Messukeskus Helsinki, Rautatieläisenkatu 3, Helsinki (Siipi entrance), on Monday, 30 March 2020, starting at 13.00 EET. The reception desks for those registered for the meeting will open and voting tickets will be provided starting from 12.00 EET. Refreshments will be served after the meeting.A. Items on the agenda of the General Meeting 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinise the minutes and to supervise the counting of votes 4.

Stora Enso shares converted

STORA ENSO OYJ STOCK EXCHANGE RELEASE 14 February 2020 at 9.00 EETDuring the 1 January 2020 – 31 January 2020 conversion period there were two conversions and a total of 850 A shares were converted into R shares. The shares were recorded in the Finnish trade register today, 14 February 2020, and trading in the new R shares will start on 17 February 2020.Breakdown of shares after conversion:  A shares 176 255 984R shares 612 364 003Total 788 619 987 Each A share and each ten R shares carry one vote. The total amount of votes after the conversion is at least 237 492 384.

Year-end report 2019

Quarter 4, 2019 · Incoming orders amounted to SEK 1,140.7m (967.8), which currency adjusted is an increase of 18.1 percent compared with the same period last year. · Net sales amounted to SEK 1,086.5m (1,069.0), which currency adjusted is an increase of 1.8 percent compared with the same period last year. · Operating profit was SEK 108.7m (120.0)*, giving an operating margin of 10.0 percent 11.2)*. · Adjusted operating profit was SEK 113.2m (129.4)*, giving an adjusted operating margin of 10.4 percent (12.1)*. · Net profit was SEK 72.4m (89.4)*. · Earnings per share were

There are no items matching the current filter
There are no more items matching the current filter
Back to top